[Skip to Content]
[Skip to Content Landing]
Views 6,360
Citations 0
News From the Food and Drug Administration
April 16, 2019

New Therapy for Treatment-Resistant Depression

JAMA. 2019;321(15):1449. doi:10.1001/jama.2019.3596

The FDA has approved esketamine nasal spray as an adjunctive therapy for adults with treatment-resistant depression (TRD), which affects approximately 30% of patients with major depressive disorder. It’s the first regulatory approval of esketamine, the s-enantiomer of ketamine, for any psychiatric condition worldwide.